Interpretation of updated NCCN guidelines for non-small cell lung cancer (version 1, 2022)
- VernacularTitle:2022年V1版《NCCN非小细胞肺癌临床实践指南》更新解读
- Author:
Zheng JIAN
1
;
Xueyu CHEN
1
;
Yajie ZHANG
1
;
Hecheng LI
1
Author Information
1. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
NCCN guidelines;
update of guideline;
interpretation of guideline
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2022;29(02):150-157
- CountryChina
- Language:English
-
Abstract:
The National Comprehensive Cancer Network (NCCN) has updated and released the latest content of the NCCN guidelines for the clinical diagnosis and treatment of non-small cell lung cancer (NSCLC) in the version 1, 2022. Based on high-quality clinical evidence and the latest research progress of the diagnosis and treatment of NSCLC, the guidelines have been widely recognized and welcomed by clinicians around the world. Compared with the version 7, 2021, the new version has been updated and revised in some parts of chapters and sections, mainly focusing on targeted therapies and molecular testing. This article will interpret the updated therapy content of the new version.
